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background: Elevation in serum phosphorus has been identified as a risk factor for adverse outcomes across the spectrum of cardiovascular 
disease, including heart failure (HF). Notably, this finding appears to be independent of glomerular filtration rate (GFR). Several biologically plausible 
pathways exist by which elevated phosphorus could directly contribute to cardiovascular pathology. Cardio-renal pathways that cause sodium avidity 
(i.e. renal neurohormonal activation) also cause increased reabsorption of phosphorus. We hypothesized that the latter may be driving much of the 
observed association between serum phosphorus and outcomes.
Methods: Subjects with chronic heart failure in the Beta-Blocker Evaluation of Survival Trial limited dataset (n=2707) were studied. The blood urea 
nitrogen (BUN) and uric acid concentrations were used as surrogates for activation of renal sodium conserving pathways.
results: Similar to previous studies, phosphorus was strongly associated with mortality in a univariate model (HR=1.4 95% CI 1.2-1.5 per mg/
dl, p<0.0001) and after controlling for estimated GFR (HR=1.2, 95% CI 1.1-1.4 per mg/dl, p<0.0001). The association remained significant in a 
multivariate model with additional adjustment for patient age, sex, race, medications, heart rate, blood pressure, ejection fraction, hemoglobin, HF 
symptoms, duration of HF, diabetes, hypertension, and coronary artery disease (HR=1.2 95% CI 1.0-1.3 per mg/dl, p=0.011). However, adjusting 
for only BUN and uric acid largely eliminated the association between phosphorus and mortality (HR=1.08 95% CI 0.97-1.2 per mg/dl, p=0.13). 
Similarly, this association remained insignificant when BUN and uric acid were added to the multivariate model described above (HR=1.07 95% CI 
0.95-1.2 per mg/dl, p=0.25).
conclusion: In the setting of chronic heart failure, the risk associated with higher serum phosphorus levels appears to primarily serve as a 
reflection of concomitant cardio-renal dysfunction rather than an independent effect of elevated serum phosphorus.
